Trials of exercise and dietary interventions have historically excluded those with stage IV disease, therefore evidence to inform service provision and recommendations for those living with a metastatic diagnosis has been limited. Unlike the large body of evidence on the detrimental association between excess body weight and prognosis in early stage breast cancer, the limited evidence specifically in those with metastatic disease suggests that excess body weight (defined by body mass index >25 and/or 30kg/m2) is not associated with poorer prognosis compared to those with a healthy body weight (20-25kg/m2) and may in fact be protective. Despite this evidence, in our trial evaluating a 12-month exercise and dietary intervention compared to current practice, in 201 women diagnosed with metastatic breast cancer across Australia, half of the intervention participants had a personal goal to lose weight. Increasing (social) media coverage on the potential benefits of glucagon-like peptide-1 (GLP-1) receptor agonist use in observational studies of those with a breast cancer diagnosis, has also sparked interest on the use of these medications in those with metastatic breast cancer. This presentation will summarise and critique existing evidence contributing to consumer (mis)information and share insights from those participating in our Optimising Care intervention.